Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.69 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28078567 | 1.00 | TSHR (0.69) | TSHRTDP1NAPRTNOTUMMEN1 | |
| Pyridine SCHEMBL31024706 | 1.00 | TSHR (0.69) | TSHRTDP1NAPRTNOTUMMEN1 | |
| Pyridine SCHEMBL1172941 | 1.00 | TSHR (0.69) | TSHRTDP1NAPRTNOTUMMEN1 | |
| Pyridine SCHEMBL3281597 | 0.96 | TSHR (0.64) | TSHRTDP1NAPRTNOTUMMEN1 | |
| Pyridine SCHEMBL31655458 | 0.96 | TSHR (0.64) | TSHRTDP1NAPRTNOTUMMEN1 | |
| Pyridine SCHEMBL6532110 | 0.88 | — | — | |
| Pyridine SCHEMBL28067297 | 0.88 | NAPRT (0.90) | TSHRTDP1NAPRTNOTUMMEN1 | |
| Pyridine SCHEMBL8023624 | 0.86 | TSHR (0.60) | TSHRTDP1NAPRTNOTUM | |
| Pyridine SCHEMBL7994810 | 0.86 | TSHR (0.60) | TSHRTDP1NAPRTNOTUM | |
| Pyridine SCHEMBL10815564 | 0.86 | TSHR (0.60) | TSHRTDP1NAPRTNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508298-B2 | Protein complex by use of a specific site of an immunoglobulin fragment for linkage | HANMI PHARM. CO., LTD. (KR) | 2025-12-30 | — | — | US | claimed |
| US-20250197466-A1 | METHODS OF TREATMENT USING G-CSF PROTEIN COMPLEX | ASSERTIO SPECIALTY PHARMACEUTICALS, LLC | 2025-06-19 | — | — | US | claimed |
| US-20250115953-A1 | Methylcytosine-Selective Deaminases and Uses Thereof | NEW ENGLAND BIOLABS, INC. (US) | 2025-04-10 | — | — | US | claimed |
| EP-4534107-A2 | PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE | Hanmi Pharm. Co., Ltd. (KR) | 2025-04-09 | — | — | EP | claimed |
| CN-119684330-A | Preparation method of bisazo pyridine borate@quantum dot fluorescent probe | 北京印刷学院 | 2025-03-25 | — | — | CN | claimed |
| CN-117219773-A | Positive electrode slurry and preparation method thereof | 宁波容百新能源科技股份有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-112920813-B | Photo-thermal response chiral photosensitive liquid crystal dopant containing azobenzene binaphthyl | 湘潭大学 | 2023-08-22 | — | — | CN | claimed |
| CN-116535311-A | Novel synthesis method of Carbonic acid | 风火轮(上海)生物科技有限公司 | 2023-08-04 | — | — | CN | claimed |
| CN-115340543-B | Positive ion type cyclopean and application thereof in preparing pharmaceutical preparation for removing photodynamic therapy residues | 复旦大学 | 2023-07-07 | — | — | CN | claimed |
| CN-108136276-B | Protein complexes linked by using specific sites of immunoglobulin fragments | 韩美药品株式会社 | 2023-02-28 | — | — | CN | claimed |
| WO-2005047336-A1 | PROTEIN COMPLEX USING IMMUNOGLOBULIN FRAGMENT ANDMETHOD FOR THE PREPARATION THEREOF | HANMI PHARMACEUTICAL. CO. LTD. (KR) | 2005-05-26 | — | — | WO | claimed |
| WO-2004083242-A1 | HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR CONJUGATE HAVING ENHANCED STABILITY IN BLOOD AND PROCESS FOR THE PREPARATION THEREOF | HANMI PHARM. CO. LTD. (KR) | 2004-09-30 | — | — | WO | claimed |
| WO-2004081053-A1 | PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | HANMI PHARM. CO. LTD. (KR) | 2004-09-23 | — | — | WO | claimed |
| US-20040181035-A1 | Modified colony stimulating factor for treatment of hematopoietic disorder | AMGEN, INC. | 2004-09-16 | — | — | US | claimed |
| US-20040180054-A1 | Physiologically active polypeptide conjugate having prolonged in vivo half-life | HANMI PHARM. CO., LTD. | 2004-09-16 | — | — | US | claimed |
| US-20030096400-A1 | N-terminally chemically modified protein compositions and methods | AMGEN, INC. | 2003-05-22 | — | — | US | claimed |
| US-20030053982-A1 | N-terminally chemically modified protein compositions and methods | KINSTLER OLAF B (US) | 2003-03-20 | — | — | US | claimed |
| JP-3177251-B2 | — | — | 2001-06-18 | — | — | JP | claimed |
| EP-0733067-A1 | N-TERMINALLY CHEMICALLY MODIFIED PROTEIN COMPOSITIONS AND METHODS | AMGEN INC. (US) | 1996-09-25 | — | — | EP | claimed |
| WO-1996011953-A1 | N-TERMINALLY CHEMICALLY MODIFIED PROTEIN COMPOSITIONS AND METHODS | AMGEN INC. (US) | 1996-04-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181035-A1 | Modified colony stimulating factor for treatment of hematopoietic disorder | CSF3R, GMFG, HCLS1 | TSHR 3051/4885TDP1 4057/4885NAPRT 3307/4885 |
| US-20030096400-A1 | N-terminally chemically modified protein compositions and methods | PTMS, NGLY1, ACP1 | TSHR 3426/4885TDP1 2631/4885NAPRT 1323/4885 |
| US-20030053982-A1 | N-terminally chemically modified protein compositions and methods | PTMS, NGLY1, ACP1 | TSHR 3426/4885TDP1 2631/4885NAPRT 1323/4885 |
| US-12508298-B2 | Protein complex by use of a specific site of an immunoglobulin fragment for linkage | FCGR3B, FCGR2A, FCER2 | TSHR 634/4885TDP1 4709/4885NAPRT 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.